Seattle-based AI drug discovery startup Talus Biosciences has secured USD 2.3 million in non-dilutive grant funding from the Andy Hill Cancer Research Endowment (CARE) Fund and an additional USD 2 million small business innovation research (SBIR) grant from the National Institutes of Health, which brings a total fund of USD 4.3 million.
The funding will be used to speed up the development of novel transcription factor inhibitors for two pediatric cancers, rhabdomyosarcoma and neuroblastoma, and accelerate the development of transcription factor drugs.
Founded in 2020, Talus Biosciences develops novel therapeutics focusing on previously undruggable transcription factors—proteins that regulate all genes in a person's genetic material by attaching to DNA and activating or deactivating the switches that determine gene activity. The company leverages its proprietary drug discovery platform, Multiplexed Assays for Rational Modulation of Transcription Factors (MARMOT), which combines AI, synthetic chemistry, and proteomics to accelerate the discovery and development of novel drugs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.